UBA1 Antibody

What is UBA1 and why is it important in cellular research?

UBA1 (also known as UBE1) is the primary E1 ubiquitin-activating enzyme that catalyzes the initial step in the ubiquitination cascade. It activates ubiquitin by adenylating its C-terminal glycine residue with ATP, followed by linking this residue to a cysteine residue in E1, forming a ubiquitin-E1 thioester bond and releasing AMP . This activation is essential for subsequent transfer to E2 enzymes and eventual protein ubiquitination.

UBA1 is crucial for research because it orchestrates protein degradation through the ubiquitin-proteasome system, influences DNA damage response pathways by promoting recruitment of TP53BP1 and BRCA1 to DNA damage sites, and has been implicated in various disease mechanisms including inflammation and cancer immune evasion . As a master regulator of ubiquitination, studying UBA1 provides insights into fundamental cellular processes and disease mechanisms.

How can I select the appropriate UBA1 antibody for my specific experimental application?

Selection of a UBA1 antibody should be guided by several experimental considerations:

• Application compatibility: Confirm the antibody has been validated for your specific application (WB, IHC-P, ICC/IF, etc.). For example, some UBA1 antibodies are specifically validated for Western blotting but not immunoprecipitation .

• Species reactivity: Verify cross-reactivity with your experimental model organism. UBA1 is highly conserved, but antibody epitope recognition can vary between species .

• Isoform specificity: UBA1 has multiple isoforms - ensure the antibody recognizes your isoform of interest. The antibody epitope location should be evaluated relative to known functional domains (UFD domain, catalytic cysteine region) .

• Validation evidence: Review published literature citing the antibody and examine validation data provided by manufacturers, particularly focusing on specificity demonstrated by knockout controls or domain-specific recognition patterns .

• Polyclonal vs. monoclonal: Polyclonal antibodies (like the rabbit polyclonal described in search result ) offer broader epitope recognition, while monoclonal antibodies provide higher specificity for particular epitopes.

For mechanistic studies involving UBA1-E2 interactions, antibodies recognizing the UFD domain would be particularly relevant, as this region mediates E2 binding and has been identified as critical in disease contexts .

What controls should I include when using UBA1 antibodies in my experiments?

Rigorous experimental design requires multiple controls:

• Positive control: Include samples known to express UBA1 (most mammalian cell lysates, as UBA1 is ubiquitously expressed)

• Negative controls:

  • UBA1 knockout or knockdown samples where available

  • Secondary antibody-only controls to assess non-specific binding

  • Isotype controls to evaluate Fc receptor binding in IF/IHC applications

• Loading controls: For quantitative Western blot, include housekeeping proteins that don't interact with UBA1 in the ubiquitination pathway

• Competition assays: Pre-incubation of antibody with immunizing peptide to verify specificity

• Validation across techniques: Confirm findings using orthogonal methods (e.g., mass spectrometry validation of immunoprecipitated samples)

A particularly important control for UBA1 functional studies is temperature manipulation, as demonstrated in the CHO ts20 cell system where UBA1 thermolability can be assessed at different temperatures (35-43°C) . This allows differentiation between wild-type and mutant UBA1 function.

How can I effectively use UBA1 antibodies for studying protein ubiquitination pathways?

UBA1 antibodies can be employed in multiple experimental approaches to study ubiquitination:

• Co-immunoprecipitation (co-IP) studies: UBA1 antibodies can be used to capture UBA1 and its interacting partners. This approach revealed that the drug Auranofin (AF) enhanced UBA1-UBE2G2 interaction, suggesting its mechanism of action involves modulation of UBA1 activity .

• Proximity-based assays: Combining UBA1 antibodies with antibodies against E2 enzymes in proximity ligation assays can visualize their interactions in situ and reveal spatial regulation of ubiquitination initiation.

• Ubiquitination cascade analysis: In sequential ubiquitination assays, monitor UBA1-Ub thioester formation using non-reducing SDS-PAGE followed by immunoblotting with UBA1 antibodies. This approach was used to demonstrate that UBA1 disease variants have altered thioester formation capacity .

• E2 recruitment studies: UBA1 antibodies can help identify which of the approximately 40 E2 enzymes interact with UBA1 under different conditions. Mass spectrometry following UBA1 immunopurification revealed that 20 of 24 detected E2 enzymes showed enhanced interaction with UBA1 in the presence of Auranofin .

• Inhibitor studies: UBA1 antibodies can monitor changes in UBA1 levels or post-translational modifications in response to inhibitors like TAK-243, which has shown synergistic effects with immune checkpoint blockade therapy .

What are the best practices for optimizing UBA1 antibody-based immunoprecipitation experiments?

Optimizing UBA1 immunoprecipitation requires careful consideration of several factors:

• Lysis conditions: Use gentle lysis buffers that preserve protein-protein interactions. For studying UBA1-E2 interactions, EDTA should be avoided as it can disrupt the Mg²⁺-dependent ATP binding necessary for ubiquitin activation .

• Antibody selection: Choose antibodies raised against epitopes that don't interfere with protein-protein interaction domains, particularly the UFD domain which mediates E2 binding .

• Cross-linking considerations: For transient interactions characteristic of enzyme-substrate relationships, consider using reversible cross-linking agents prior to cell lysis.

• Reducing vs. non-reducing conditions: To capture UBA1~ubiquitin thioester intermediates, samples should be processed under non-reducing conditions that preserve the thioester bond .

• Validation approaches: Confirm specificity using reciprocal immunoprecipitation, as demonstrated in the Auranofin study where both UBA1 and UBE2G2 antibodies were used in reciprocal co-IP experiments .

• Scale and sensitivity: For detecting low-abundance E2 interaction partners, consider using label-free quantitative mass spectrometry after UBA1 immunoprecipitation, which successfully identified 24 E2 enzymes interacting with UBA1 .

How can I differentiate between active and inactive UBA1 using antibody-based techniques?

Differentiating active from inactive UBA1 requires specialized approaches:

• Thioester formation assay: Active UBA1 forms a thioester bond with ubiquitin, which can be detected using non-reducing SDS-PAGE followed by immunoblotting with UBA1 antibodies. The active form appears as a higher molecular weight band (~8kDa larger) corresponding to the UBA1~Ub thioester intermediate .

• Thermal shift assays: The Cellular Thermal Shift Assay (CETSA) can detect conformational changes in UBA1 upon binding ligands like ATP or inhibitors. This approach demonstrated that Auranofin enhances UBA1 thermal stability, indicating direct binding .

• E2 charging assays: Active UBA1 transfers ubiquitin to E2 enzymes, which can be monitored using a two-step assay:

  • Pre-incubate UBA1 with ubiquitin and ATP

  • Add EDTA to prevent new thioester formation

  • Add E2 enzyme and monitor ubiquitin transfer

  • Detect charged E2 by immunoblotting or using fluorescent ubiquitin

• Kinetic analysis: For quantitative assessment of UBA1 activity, measure the rate of ATP-PPi exchange or AMP formation in the presence of ubiquitin, which requires combining immunoprecipitation with activity assays.

• Thermolability comparison: Disease-associated UBA1 variants often show increased thermolability. This can be assessed by pre-incubating UBA1 at various temperatures (35-43°C) before measuring activity, allowing differentiation between wild-type and mutant forms .

How are UBA1 antibodies used to investigate the role of UBA1 in cancer immune evasion?

UBA1 antibodies have been instrumental in uncovering the role of UBA1 in cancer immune evasion:

• Expression correlation studies: UBA1 antibodies enable quantification of UBA1 expression in tumor samples, which has been negatively correlated with signatures related to effector CD8+ T cells, suggesting a role in immune evasion .

• Mechanistic investigation: Immunoblotting with UBA1 antibodies revealed that the UBA1-STUB1 axis regulates JAK1 stability, a key component of interferon signaling. UBA1 depletion or inhibition stabilized JAK1, enhancing interferon signaling and elevating immune modulators including CXCL9, CXCL10, and MHC class I .

• Therapeutic response prediction: Immunohistochemistry with UBA1 antibodies in patient samples showed that high UBA1 expression strongly predicted resistance to immune checkpoint blockade therapy and poor survival in treated cohorts .

• In vivo functional studies: UBA1 antibodies helped demonstrate that UBA1 overexpression or depletion markedly affected functional intratumoral CD8+ T cells, directly linking UBA1 levels to anti-tumor immunity .

• Drug response monitoring: UBA1 antibodies can monitor changes in UBA1 activity and downstream signaling following treatment with UBA1 inhibitors like TAK-243, which synergized with immune checkpoint blockade in multiple cancer models .

These findings position UBA1 as both a potential biomarker for immunotherapy response and a therapeutic target to enhance cancer immunotherapy efficacy.

What methods can be used to study UBA1 mutations associated with VEXAS syndrome?

VEXAS syndrome is associated with somatic UBA1 mutations, and several specialized methods can be employed to study these mutations:

• Mutation detection approaches:

  • Sanger sequencing for known hotspot mutations (e.g., p.Met41Val/Thr/Leu)

  • Exome sequencing for novel mutation discovery

  • Digital droplet PCR (ddPCR) for detection of low variant allele fractions (VAF), which successfully identified a p.Met41Val mutation with only 9% VAF

• Cell lineage analysis: UBA1 antibodies can be used with lineage markers to determine which hematopoietic cell populations carry the mutation, helping explain the multi-system inflammatory manifestations.

• Functional characterization:

  • In vitro UBA1 ubiquitin thioester formation assays to assess how mutations affect the first step of the ubiquitination cascade

  • Thermolability assays comparing wild-type and mutant UBA1 at temperatures from 35-43°C, which revealed that disease-associated variants have increased temperature sensitivity

  • E2 ubiquitin transfer assays to evaluate the efficiency of ubiquitin transfer to downstream E2 enzymes

• Cellular modeling: The CHO ts20 cell system, which carries a temperature-sensitive UBA1 mutation, provides a platform to evaluate UBA1 mutant function under permissive and non-permissive temperatures .

• Patient-derived models: Using patient samples carrying UBA1 mutations to establish primary cell cultures or xenografts for studying disease mechanisms in a physiologically relevant context.

How can UBA1 antibodies be used to evaluate the efficacy of UBA1-targeting therapeutics?

UBA1 antibodies are crucial for evaluating UBA1-targeting therapeutics through several approaches:

• Target engagement assessment:

  • Cellular Thermal Shift Assay (CETSA) with UBA1 antibodies can confirm direct binding of compounds to UBA1 in cells, as demonstrated with Auranofin

  • Monitoring conformational changes in UBA1 upon inhibitor binding using limited proteolysis followed by immunoblotting

• Pathway modulation evaluation:

  • Measuring changes in global ubiquitination levels following treatment

  • Assessing specific substrate accumulation (e.g., JAK1 stabilization) that occurs when UBA1 is inhibited

  • Monitoring downstream signaling pathways, particularly interferon signaling components

• Combination therapy studies:

  • Using UBA1 antibodies to assess changes in immune-related proteins when UBA1 inhibitors are combined with immunotherapies

  • Tracking expression of immune modulators (CXCL9, CXCL10, MHC class I) that increase following UBA1 inhibition

• Biomarker development:

  • Quantifying UBA1 levels in patient samples to potentially predict response to immunotherapy

  • Assessing UBA1 activity states before and after treatment as a pharmacodynamic marker

• Resistance mechanism investigation:

  • Using UBA1 antibodies to identify compensatory mechanisms that emerge following long-term UBA1 inhibition

  • Examining alterations in UBA1 binding partners or post-translational modifications that might confer resistance

What are the challenges in using UBA1 antibodies for studying UBA1-E2 enzyme interactions, and how can they be overcome?

Studying UBA1-E2 interactions presents several challenges that require specialized approaches:

• Transient nature of interactions:

  • Challenge: UBA1-E2 interactions are often transient and ATP/Mg²⁺-dependent.

  • Solution: Use stabilizing agents like Auranofin that enhance UBA1-E2 binding , or employ crosslinking approaches before immunoprecipitation.

• Specificity among multiple E2 enzymes:

  • Challenge: UBA1 interacts with numerous E2 enzymes with varying affinities.

  • Solution: Employ quantitative mass spectrometry after UBA1 immunoprecipitation to identify and quantify the full spectrum of interacting E2s, as demonstrated in the Auranofin study that identified 24 E2 enzymes interacting with UBA1 .

• Conformational states:

  • Challenge: UBA1 undergoes significant conformational changes during its catalytic cycle.

  • Solution: Use conformation-specific antibodies or compare reducing vs. non-reducing conditions to capture different states.

• Competition between E2s:

  • Challenge: E2 enzymes compete for binding to the UFD domain of UBA1.

  • Solution: In vitro competition assays using purified components and antibody detection of bound E2s can reveal hierarchies of interaction.

• Subcellular localization:

  • Challenge: UBA1-E2 interactions may occur in specific cellular compartments.

  • Solution: Combine proximity ligation assays with subcellular markers to visualize interactions in their native context.

• Functional validation:

  • Challenge: Detecting interaction doesn't confirm functional ubiquitin transfer.

  • Solution: Complement interaction studies with E2~Ub thioester formation assays to confirm productive enzyme interactions .

How can advanced microscopy techniques be combined with UBA1 antibodies to study ubiquitination dynamics in living cells?

Advanced microscopy combined with UBA1 antibodies enables visualization of ubiquitination dynamics:

• Super-resolution microscopy:

  • Stimulated Emission Depletion (STED) or Stochastic Optical Reconstruction Microscopy (STORM) with UBA1 antibodies can resolve the spatial organization of ubiquitination initiation sites at sub-diffraction resolution.

  • Multi-color super-resolution imaging can visualize UBA1 co-localization with E2 enzymes and potential substrates.

• Live-cell proximity sensors:

  • FRET (Förster Resonance Energy Transfer) biosensors incorporating UBA1 and E2 enzymes can monitor their interactions in real-time.

  • Split-fluorescent protein complementation assays where UBA1 and E2s are tagged with complementary fragments that fluoresce only when in proximity.

• Spatiotemporal activity mapping:

  • PhotoActivatable-GFP (PA-GFP) fused to UBA1 allows tracking of activated pools of the enzyme.

  • Optogenetic approaches to locally activate UBA1 combined with antibody-based detection of resulting ubiquitination.

• Correlative microscopy:

  • Combine live-cell imaging with fixed-cell antibody staining using correlative light and electron microscopy (CLEM) to connect dynamic events with ultrastructural context.

• Single-molecule tracking:

  • Using quantum dot-conjugated UBA1 antibody fragments (Fab) to track individual UBA1 molecules in living cells, revealing diffusion rates and residence times at potential substrate sites.

• Microfluidic approaches:

  • Microfluidic devices allow precise temporal control of drug addition while monitoring UBA1 localization and activity, particularly useful for studying inhibitor effects or stress responses.

What methodological approaches can be used to distinguish UBA1-dependent ubiquitination from UBA6-dependent pathways using antibody-based techniques?

Distinguishing UBA1 from UBA6 activities requires specialized methodological approaches:

• Isoform-specific antibodies:

  • Use antibodies targeting unique epitopes in UBA1 (e.g., the UFD domain) that are distinct from those in UBA6.

  • Validate antibody specificity using knockout or knockdown controls for each E1.

• Substrate profiling:

  • UBA1 and UBA6 preferentially work with different sets of E2 enzymes - UBA6 uniquely works with USE1.

  • Immunoprecipitate UBA1 or UBA6 and identify associated E2s by mass spectrometry to establish pathway-specific components.

• Sequential immunodepletion:

  • Selectively deplete UBA1 using specific antibodies, then assay remaining ubiquitination activity (which would be UBA6-dependent).

  • The reciprocal experiment can isolate UBA1-dependent activity.

• Inhibitor studies:

  • Some UBA1 inhibitors like TAK-243 have different potencies against UBA1 versus UBA6.

  • Dose-response studies with immunoblotting can differentiate between pathways based on inhibitor sensitivity.

• Ubiquitin variant utilization:

  • UBA6 can activate both ubiquitin and FAT10, whereas UBA1 only activates ubiquitin.

  • Using antibodies against FAT10 conjugates can identify specifically UBA6-dependent modifications.

• Genetic complementation:

  • In UBA1-depleted systems, reintroduce wild-type or mutant UBA1 and assess rescue of specific ubiquitination events.

  • This approach can identify which substrates strictly require UBA1 versus those that can be compensated for by UBA6.

What are common technical issues with UBA1 antibodies and how can they be resolved?

Researchers frequently encounter several technical challenges when working with UBA1 antibodies:

• Non-specific binding:

  • Issue: Additional bands in Western blots or non-specific staining in immunofluorescence.

  • Resolution: Optimize antibody concentration, increase blocking stringency (5% BSA instead of milk for phosphorylation-sensitive applications), and include additional washing steps with increased salt concentration.

• Epitope masking:

  • Issue: UBA1 interacts with numerous proteins which may block antibody access to epitopes.

  • Resolution: Try different antibodies targeting distinct epitopes, or use denaturing conditions for applications like Western blotting.

• Post-translational modifications:

  • Issue: PTMs may alter antibody recognition or create multiple bands.

  • Resolution: Use phosphatase treatment or ubiquitin-specific proteases to determine if bands represent modified forms of UBA1 rather than non-specific binding.

• Isoform specificity:

  • Issue: Human UBA1 has multiple isoforms from alternative splicing.

  • Resolution: Verify which isoform(s) your antibody recognizes and design experiments accordingly.

• Fixation sensitivity:

  • Issue: Some epitopes are sensitive to fixation methods in immunohistochemistry.

  • Resolution: Compare multiple fixation protocols (formalin, methanol, acetone) to determine optimal conditions for epitope preservation.

• Antibody batch variation:

  • Issue: Different lots may show varying specificity and sensitivity.

  • Resolution: Validate each new lot against a reference sample and consider creating a standard curve with recombinant UBA1.

How can researchers validate the specificity of UBA1 antibodies in their experimental systems?

Thorough validation of UBA1 antibodies is essential for reliable results:

• Genetic validation:

  • Use UBA1 knockout or knockdown systems (siRNA, CRISPR) to confirm specificity.

  • Overexpression of tagged UBA1 should result in an additional band or increased signal intensity.

• Peptide competition:

  • Pre-incubate antibody with the immunizing peptide to block specific binding.

  • Specific signals should disappear while non-specific ones remain.

• Multiple antibody validation:

  • Use antibodies from different sources that recognize distinct epitopes.

  • Concordant results with multiple antibodies increase confidence in specificity.

• Orthogonal techniques:

  • Confirm antibody-based results using mass spectrometry, which can identify UBA1 based on peptide sequences rather than epitope recognition.

• Functional correlation:

  • Verify that signals change as expected with treatments known to affect UBA1 function (e.g., proteasome inhibitors or UBA1 inhibitors like TAK-243).

• Species-specificity testing:

  • Test the antibody across relevant model organisms if cross-reactivity is claimed.

  • Sequence alignment of the epitope region can predict likely cross-reactivity.

• Domain-specific mutation:

  • Introduce mutations in specific UBA1 domains and confirm altered antibody recognition if the epitope is in that region.

What quantitative approaches can be used to accurately measure UBA1 protein levels and activity in complex biological samples?

Accurate quantification of UBA1 requires specialized approaches: